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Determination of the urinary or plasma clearance of
exogenous renal markers, such as inulin or iohexol, is
considered to be the gold standard for glomerular filtration
rate (GFR) measurement. Here, we describe a technique
allowing determination of renal function based on
transcutaneously measured elimination kinetics of
fluorescein isothiocyanate (FITC)-sinistrin, the FITC-labeled
active pharmaceutical ingredient of a commercially available
marker of GFR. A low cost device transcutaneously excites
FITC-sinistrin at 480nm and detects the emitted light through
the skin at 520nm. A radio-frequency transmission allows
remote monitoring and real-time analysis of FITC-sinistrin
excretion as a marker of renal function. Due to
miniaturization, the whole device fits on the back of freely
moving rats, and requires neither blood sampling nor
laboratory assays. As proof of principle, comparative
measurements of transcutaneous and plasma elimination
kinetics of FITC-sinistrin were compared in freely moving
healthy rats, rats showing reduced kidney function due to
unilateral nephrectomy and PKD/Mhm rats with cystic kidney
disease. Results show highly comparable elimination half-
lives and GFR values in all animal groups. Bland–Altman
analysis of enzymatically compared with transcutaneously
measured GFR found a mean difference (bias) of 0.01 and a
0.30 to 0.33ml/min per 100g body weight with 95% limit
of agreement. Thus, with this device, renal function can be
reliably measured in freely moving rats eliminating the need
for and influence of anesthesia on renal function.
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Glomerular filtration rate (GFR) is the best parameter
reflecting overall kidney function. Determination of the
urinary or plasma clearance of exogenous renal markers, such
as inulin or iohexol, is considered to be as gold standard for
GFR measurement.1 As these procedures are very time
consuming and cumbersome, they are neither routinely used
in clinical practice nor in the characterization of animal
models.1
Because of the lack of an easy to handle, precise GFR
measurement there are several approaches aiming at the
simplification of exogenous clearance procedures.2,3 Although
these techniques still rely on blood and/or urine sampling
and laboratory assays. Other experimental approaches
are based on the transcutaneous determination of the
elimination kinetics of either fluorescent,4–9 radioactive,10
or gadolinium-labeled11 exogenous GFR markers. The major
advantages of these procedures are their independence of
blood and/or urine sampling and laboratory assays, thus
allowing kidney function measurement almost in real time,
hence making the detection of rapid changes in renal function
(for example, in acute renal failure) possible.12 A major dis-
advantage of these techniques in the view of animal experiments,
however, is that animals need to be anesthetized during the
measurement, resulting in an influence of the anesthesia on
renal function.13,14 Moreover GFR cannot be determined by
classical single or multiple compartment models, as only
relative changes in fluorescence, radiation, or magnetic resonance
contrast can be determined, but not total concentrations.
Hence, these techniques are restricted to the determination of
the rate constant (m) or excretion half-life (¼ ln2/m) of the
latter single exponential excretion phase of the exogenous
markers. It has been shown, that this rate constant is a very
close estimate of GFR/extracellular volume space, therewith
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being a valid parameter reflecting renal function.15 The
theoretical background of this fact is beyond the scope of this
Technical Note, the interested reader is referred to recent
literature.15
In this Technical Note, we focus on a novel device for the
transcutaneous measurement of the elimination kinetics of
the fluorescent-labeled exogenous GFR marker fluorescein
isothiocyanate (FITC)-sinistrin7,16,17 in freely moving rats.
DEVICE
The miniaturized and flexible instrument is built up from a
light-emitting diode with an emission maximum for FITC at
480 nm (ELS-525-892 EPIGAP Optoelektronik GmbH,
Berlin, Germany) and a photodiode that detects the emitted
light at 520 nm (EPD-525-1-0.9-1 EPIGAP Optoelektronik
GmbH). To select the appropriate wavelength, a blue resp.
green bandpass filter is placed in front of the light-emitting
diode and photodiode (071 Tokyo Blue,o500 nm, 015 Deep
Straw,4480 nm, Lee Filters, Andover, England). After highly
sensitive amplification and digitization (10 bit), the data are
transferred over radio frequency (EZ430-RF2500, Board Kit,
MSP430, Texas Instruments) to a remote PC, in which the kinetic
parameters are determined. For use on awake rats, the local
energy is supplied by a small accumulator battery. The optical
part of the device and its building blocks are shown in Figure 1.
FITC-Sinistrin
Sinistrin is the active pharmaceutical ingredient of the
commercially available GFR marker Inutest (Fresenius Kabi,
Linz, Austria). The labeling reaction has been described
elsewhere.16,17
PROOF OF PRINCIPLE
Simultaneous measurements of transcutaneous and plasma
elimination kinetics of FITC-sinistrin were performed in
freely moving healthy rats (n¼ 7) and rats having reduced
kidney function due to unilateral nephrectomy (n¼ 5) or
cystic kidney disease (7 months old PKD/Mhm rats,18 n¼ 6).
The electronic part is incorporated into a rodent jacket
(Lomir Biomedical, Malone, NY), whereas the optical
components are fixed on a depilated region on the back of
the rat using a sticky patch (Lohmann GmbH KG, 56567,
Neuwied, Germany). All animal experiments were performed
according to international and local regulations/guidelines
equivalent to the NIH Guide for the Care and Use of
Laboratory Animals.
For the experiment the animals were prepared, as
described previously.7,16,17 After a baseline period, where
the system detects a constant background signal, FITC-
sinistrin (63mg per 100 g body weight (b.w.)) was injected
via a catheter into the left femoral vein. The sampling rate of
the device was 60 measurements per min, the excitation time
lasted 10ms per measurement and the whole experiment was
performed over 120min resulting in 7200 data points/session
(Figure 2a). The FITC-sinistrin elimination kinetics were
simultaneously assessed transcutaneously, as well as fluor-
ometrically in plasma samples. Moreover, the fructan moiety
of the FITC-sinistrin was determined enzymatically in plasma
samples as a gold standard technique of GFR measurement,
as published before.7,16,17,19 From the plasma samples the rate
constant and elimination half-life were calculated using an
established one compartment model (Figure 2b).7,16,17 In
addition, a two compartment model was fitted to the
transcutaneous data for half-life determination (see Supple-
mentary Data online).
Figure 2 shows representative excretion kinetics determined
transcutaneously as well as fluorometrically and enzymatically
in plasma.
GFR was calculated out of the derived half-lifes and a
semi-empirical approach (validated in rats) using a formula
published before:7
GFR ½ml=min =100g b:w: ¼ 31:26 ½ml=100g b:w:
t1=2 ðFITC sinistrinÞ½min
ð1Þ
COMPARISON OF MEASUREMENTS OBTAINED
TRANSCUTANEOUSLY AND IN PLASMA
Transcutaneous and plasma measurements were tolerated
well by the animals. The results of the simultaneously
performed techniques are given in Table 1. Overall, the mean
Skin
Photodiode
LED Buffer
Amplifier
Microcontroller
MSP430
RFID
Computer
Battery
a b
Figure 1 |New device. Optical part of the new device for transcutaneous measurement (a) and a schematic drawing of its building blocks
(b). LED, light-emitting diode; RFID, radio-frequency identification.
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half-life and GFR values are compared favorably. Figure 3
reveals the correlation of the simultaneously derived
enzymatically and transcutaneously derived excretion half-
lifes and GFR values. The precision of the measurements is
depicted by a Bland–Altman plot.20,21
An interesting finding is that the 95% confidence intervals
of the transcutaneous method are significantly narrower
compared with the 95% confidence intervals of the
measurements in plasma, but the standard deviation of the
plasma measurements within the animal groups are lower
compared with the transcutaneous measurements (Table 1).
The 95% confidence interval is a measure of the quality of
the curve fitting procedure. As the number of measurement
points in the transcutaneous measurement is much higher
compared with the blood sample measurement, the 95%
confidence intervals of the transcutaneous measurement has
to be narrower compared with the blood measurement for
mathematical reasons. However, this implies that because of
the more robust curve fitting procedure the transcutaneous
method might be more sensitive than the plasma measure-
ment. This higher sensitivity of the transcutaneous method
on the other hand can lead to a higher standard deviation
within the animal groups, and therewith limited precision
in the Bland–Altman plot as well as weak correlation
parameters, like r 2, in the comparison of the methods. The
reason for this is that differences in GFR might be detected by
the transcutaneous method that are not reflected by the
plasma measurements due to its poorer sensitivity. However,
there are also still issues, which have to be further
investigated that might influence the reliability of the
transcutaneous method like differences in skin thickness,
influence of altered skin perfusion by gluing the plaster to the
skin, or influence of the skin penetration depth of the light
beam. The limited number and size of the animal groups is a
further drawback in this proof of concept study.
RATE CONSTANT VERSUS GFR
In rats, either the rate constant or half-life itself can be used
as measure of kidney function. Moreover, the half-life can be
converted into GFR by an empirically derived conversion
factor8 or by curve fitting procedures in combination with an
estimated plasma volume.9 A drawback of the conversion of
the rate constant into GFR is that the distribution volumes
need to be assumed stable. This might lead to errors in some
experimental settings in which edema and changes in GFR
occur at the same time. An advantage of the rate constant as
measure of renal function is its independence in situations,
wherein extracellular volume space changes, but GFR is
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Figure 2 | Excretion kinetics. Example of a transcutaneously (a) measured disappearance curve and its counterpart measured in plasma
enzymatically as well as fluorometrically (b) after intravenous injection of 63mg per 100 g body weight fluorescein isothiocyanate (FITC)-
sinistrin dissolved in phosphate-buffered saline (400mg/ml). (a) Shows a typical example of a transcutaneously measured FITC-sinistrin
excretion kinetic and the fitted bi-exponential regression curve. The background signal of the measurement of 166.6 AU is plotted as
dashed line. (b) Gives the corresponding excretion kinetics measured in plasma and the exponential regression curve fitted to the second
part of the curve (black data points, solid line represents fluorometric measurement; black crosses, dashed line represents enzymatic
measurement). Open circles (fluorometric) and open squares (enzymatic) indicate the initial fast decrease in concentration in plasma caused
by the combination of diffusion into the interstitial space and the renal clearance of FITC-sinistrin.
Table 1 | Comparison of kinetic results and GFR determination of FITC-sinistrin in three different rat models
Enzymatic measurement
(plasma) mean±s.d.
Transcutaneous measurement
mean±s.d.
Fluometric measurement
(plasma) mean±s.d.
Animal group
GFR (ml/min
per 100g b.w.)
t1/2
(min)
95%
CI low
95% CI
high
GFR (ml/min
per 100g b.w.)
t1/2
(min)
95% CI
low
95% CI
high
GFR (ml/min
per 100g b.w.)
t1/2
(min)
95%
CI low
95%
CI high
Healthy s.d. (n=7) 1.2±0.1 26.5±1.5 23.8±3.1 30.8±2.1 1.2±0.2 27.3±3.9 27.2±3.9 27.4±3.9 1.2±0.1 25.3±1.5 20.9±1.5 34.2±4.0
UNX s.d. (n=5) 0.9±0.04 33.5±1.5 28.9±1.7 40.2±5.5 0.8±0.3 34.8±4.7 34.5±4.8 35.0±4.7 0.9±0.03 35.8±1.1 31.4±1.1 41.8±3.6
PKD/Mhn (n=6) 0.9±0.1 33.3±3.3 29.6±3.8 37.1±5.2 0.9±0.2 34.0±6.7 33.7±6.5 34.4±6.8 0.9±0.1 36.7±3.4 33.5±3.1 40.9±4.2
Abbreviations: b.w., body weight; CI, confidence interval; FITC, fluorescein isothiocyanate; GFR, glomerular filtration rate; t1/2, half-life.
The 95% confidence intervals of the derived half-lifes from the enzymatic and fluorometric (plasma) measurement show a wide range of about 7–10min, the 95% confidence
intervals of the transcutaneously derived half-lifes exhibit only a range ofo1min. This is due to the much more reliable regression analysis through the high number of data
points. It indicates a correspondingly higher precision of the transcutaneous measurement compared with the enzymatic and fluorometric measurements in plasma.
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unaffected. In such a situation, classical bolus clearance
techniques may show an apparent rise or decline in GFR.15
An additional advantage of the indexation of GFR to
extracellular volume space is its technical simplicity, as only
the rate constant needs to be determined,15 which as a
parameter is independent of dosage or injection errors.
COMPARISON TO OTHER APPROACHES
Other approaches have been published only allowing the
transcutaneous measurement of kidney function in anesthe-
tized rodents using fluorescent-labeled functional markers, in
combination with a fluorescent microscope or laser-based
measuring devices.4–9
Recently, Wang et al.9 introduced a ratiometric fluorescent
technique based on the measurement of a reporter and a
marker substance using a fluorescent microscope and a two
compartment mathematical model in anesthetized rats. The
use of a ratiometric technique to overcome movement
artifacts is of high interest especially in measurements in
freely moving animals. However, the injection of a reporter
molecule showing an excretion half-life close to infinity is not
suitable for human use, especially with respect to toxicity.
POTENTIAL FOR HUMAN APPLICATION
The described method has the potential to become a
convenient method for precise renal function measurement
in humans. It would allow monitoring renal function in
populations at high risk of developing chronic kidney failure,
similar to diabetic or hypertensive patients, predominantly in
the near normal range, when e-GFR gives unclear results.1
Other possible applications could be GFR monitoring of
patients in intensive care units with a high risk of developing
acute renal failure,11 or for dose adjustment of renally
excreted or nephrotoxic drugs, which is especially crucial in
children, elderly, and patients receiving anticancer drugs.
The limitation of the method concerning the determina-
tion of total GFR could be overcome in humans by a formula
derived by Bird et al.22 allowing the estimation of
extracellular volume space from the patients’ weight and
height. This equation makes the calculation of total GFR
from the rate constant possible.11,22
For human use, the fluorescence signal per mg substance
and the sensitivity of the device has to be improved to reach a
suitable dosage for humans. With the described settings it is
possible to transcutaneously measure FITC-sinistrin concen-
trations down to 0.07mg/ml plasma concentration (Figure 4).
IN SUMMARY
We present a device allowing the determination of renal
function in freely moving rats with no need for blood
sampling and laboratory assays. Such a method is valuable in
studies in which effects of anesthesia on GFR have to be
avoided. Because of its independence from blood sampling,
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Figure 3 |Method comparison for determination of half-life and glomerular filtration rate (GFR) in rats after intravenous injection
of FITC-sinistrin measured transcutaneously as well as enzymatically in plasma. Scatter plot of half-life (r2¼ 0.57 for y(x)¼ ax
regression function) (a) and calculated GFR (r2¼ 0.59 for y(x)¼ ax regression function) (b) with lines of identity (dashed), are depicted
(n¼ 18). Bland–Altman plot (c)20,21 shows a mean difference (bias) of 0.01ml/min per 100 g b.w. and a 95% limit of agreement of 0.30 to
0.33ml/min per 100 g b.w.
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Figure 4 | Scatter plot of transcutaneously measured emission
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(FITC)-sinistrin concentration in plasma. The plot illustrates
that a transcutaneous measurement is possible down to a plasma
concentration of about 0.07mg/ml.
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multiple/repetitive GFR determinations can be performed
within a short-time period in the same animal. Compared
with classical plasma clearance techniques the robustness of
the new technique is demonstrated in animal models without
and with renal impairment.
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